局部晚期食管鳞癌术前与术后放化疗对比研究
该研究基于全国数据库纳入1647例临床II/III期食管鳞癌(ESCC)患者,其中1245例接受术前放化疗后食管切除术(pre-OP CRT组),402例接受直接食管切除术后放化疗(post-OP CRT组),经倾向评分匹配得到286对均衡病例进行比较。匹配后两组3年总生存率与中位生存期无显著差异(44.0%/26.0个月 vs 37.9%/23.5个月,P=.3152),多因素分析中治疗模式并非OS或DFS的显著影响因素。结论认为局部晚期ESCC术后放化疗可获得与术前放化疗相似的结局。
要点
- 匹配后术前与术后放化疗组3年OS无显著差异(44.0% vs 37.9%,P=.3152)
- 3年DFS两组差异亦未达统计学显著(38.7% vs 30.2%,P=.0674)
- 多因素分析中治疗模式对OS(P=.258)与DFS(P=.521)均非显著因素
核心结论
- 局部晚期ESCC患者接受术后放化疗与术前放化疗可获得相似的治疗结局,两种策略差异不大。
研究设计与样本
- 研究基于全国数据库回顾性纳入1647例临床II/III期ESCC患者,其中pre-OP CRT组1245例、post-OP CRT组402例。
- 采用倾向评分匹配识别出286对均衡病例用于结局比较。
主要发现
- 匹配患者中,pre-OP CRT组3年OS为44.0%、中位生存26.0个月(95%CI 18.9-38.0个月),post-OP CRT组3年OS为37.9%、中位生存23.5个月(95%CI 18.5-29.9个月),P=.3152。
- 术后3年DFS/中位生存:pre-OP CRT组38.7%/16.7个月(95%CI 11.9-29.6个月),post-OP CRT组30.2%/10.4个月(95%CI 7.6-14.0个月),P=.0674。
- 完全切除患者术后1年无复发率pre-OP CRT组为74.8%、post-OP CRT组为67.6%(P=.2696)。
- 多因素分析中治疗模式(术前或术后放化疗)对OS(P=.258)与DFS(P=.521)均非显著因素。
临床怎么用
- 对于局部晚期ESCC,术前放化疗后手术与先手术后放化疗均可作为可选策略,需结合患者具体情况个体化选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Although preoperative chemoradiation followed by surgery has been recognized as an efficient strategy for esophageal cancer treatments, several studies demonstrate survival benefits of postoperative chemoradiation for those undergoing upfront resection. The optimal sequence of surgery and chemoradiation remains unclear. METHODS: Data of 1647 patients with clinical stage II/III esophageal squamous cell carcinoma (ESCC), including 1245 receiving preoperative chemoradiation followed by esophagectomy (pre-OP CRT group) and 402 receiving primary esophagectomy followed postoperative chemoradiation (post-OP CRT group), were obtained from a nationwide database. Propensity score matching identified 286 well-balanced pairs for outcome comparison. RESULTS: In matched patients, the 3-year overall survival (OS) rates/median survival were not significantly different between the 2 groups (44.0% 3-year OS/26.0 months; 95% confidence interval [CI], 18.9-89 38.0 months) in the pre-OP CRT group, versus 37.9% 3-year OS/23.5 months (95% CI, 18.5-29.9 months) in the post-OP CRT group, P = .3152). The 3-year disease-free survival rates (DFS)/median survival after surgery were 38.7% 3-year DFS/16.7 months (95% CI, 11.9-29.6 months) in the pre-OP CRT group, compared with 30.2% 3-year DFS/10.4 months (95% CI, 7.6-14.0 months) in the post-OP CRT group (P = .0674). In patients who had complete resection, the freedom from recurrence rate at 1 year after surgery was 74.8% and 67.6% in pre-OP CRT and post-OP CRT groups, respectively (P = .2696). In the multivariable analysis, treatment modality (pre- or post-OP CRT) was not a significant factor for OS (P = .258) or disease-free survival (P = .521). CONCLUSIONS: Similar outcome can be achieved with postoperative chemoradiotherapy compared with preoperative chemoradiotherapy in patients with locally advanced ESCC. There is little difference between these 2 strategies.
引用
- Hsu PK, Chen HS, Liu CC, et al. Pre- versus postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2017. PMID: 28457536. doi:10.1016/j.jtcvs.2017.03.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。